Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for… EP News Bureau Apr 10, 2025 AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…
Novel pipeline agents to drive global major depressive disorder market: GlobalData EP News Bureau Apr 7, 2021 To reach $7.9 billion by 2029 at a compound annual growth rate (CAGR) of 7.1 per cent
